Thierry Abribat

Title: Innovations in Cancer Treatment by Thierry Abribat

Introduction

Thierry Abribat is a notable inventor based in Sainte Foy Les Lyon, France. He has made significant contributions to the field of cancer treatment, particularly through his innovative work on L-asparaginase conjugates. With a total of 5 patents to his name, his research focuses on improving therapeutic options for patients with Acute Lymphoblastic Leukemia (ALL).

Latest Patents

One of Thierry Abribat's latest patents is a method of treating Acute Myeloid Leukemia (AML) with PEGylated L-asparaginase. This invention discloses a conjugate of L-asparagine aminohydrolase and polyethylene glycol, where the polyethylene glycol has a molecular weight of less than or equal to about 5000 Da. The conjugate demonstrates a high level of in vitro activity and an unexpected increase in half-life in vivo. This method is particularly useful as a second-line therapy for patients who have developed hypersensitivity or experienced a disease relapse after treatment with other L-asparaginase preparations. Another significant patent involves a pegylated L-asparaginase conjugate, which also shows superior properties for treating cancer, especially ALL.

Career Highlights

Throughout his career, Thierry Abribat has worked with prominent companies in the pharmaceutical industry. Notably, he has been associated with Jazz Pharmaceuticals and Millendo Therapeutics. His work in these organizations has allowed him to advance his research and contribute to the development of innovative cancer therapies.

Collaborations

[This section has been skipped due to space constraints.]

Conclusion

Thierry Abribat's contributions to cancer treatment through his innovative patents highlight the importance of research in improving therapeutic options for patients. His work continues to pave the way for advancements in the field of oncology.